Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 17/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 17/20 | 1.00 |
| ▸ | PDE4A | P27815 | 13/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 13/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 13/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indolidan SCHEMBL29605502 | 1.00 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10518523 | 0.84 | PDE3B (0.90) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Indolidan SCHEMBL17076620 | 0.83 | PDE3B (0.69) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7483850 | 0.83 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10520070 | 0.82 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10517412 | 0.82 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10572135 | 0.81 | PDE3B (0.67) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7433571 | 0.80 | PDE3B (0.67) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7427747 | 0.79 | PDE3B (0.74) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7636343 | 0.78 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1017 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2275095-A2 | Neurogenesis by muscarinic receptor modulation | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2010019450-A2 | SYNERGIZING ACTIVE COMPOUNDS FOR TREATING INFLAMMATION AND OTHER CONDITIONS | BAUER NYLES (US) | 2010-02-18 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-5728705-A | Method of inducing vasorelaxation to treat pulmonary hypertension | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-03-17 | — | — | US | claimed |
| EP-0777482-A1 | COMBINED PREPARATION FOR THE THERAPY OF IMMUNE DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | claimed |
| US-5552267-A | PHOSPHODIESTERASE INHIBITORS, GLUCOSE, MAGNESIUM IONS, BUFFERS, MAGNESIUM IONS AS MACROMOLECULES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1996-09-03 | — | — | US | claimed |
| WO-1996005838-A2 | COMBINED PREPARATION FOR THE THERAPY OF IMMUNE DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-02-29 | — | — | WO | claimed |
| WO-1995009636-A1 | METHOD OF INDUCING VASORELAXATION TO TREAT PULMONARY HYPERTENSION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 1995-04-13 | — | — | WO | claimed |
| US-5196416-A | Percutaneous absorption | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | claimed |
| EP-0306192-B1 | PERMEATION ENHANCEMENT COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1992-05-27 | — | — | EP | claimed |
| EP-0306192-A2 | Permeation enhancement compositions | ELI LILLY AND COMPANY (US) | 1989-03-08 | — | — | EP | claimed |
| US-4647564-A | PYRIDAZINONE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-03-03 | — | — | US | claimed |
| EP-0161918-A2 | Indoline and 2-indolinone derivatives | ELI LILLY AND COMPANY (US) | 1985-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE3B 2328/4885PDE3A 2619/4885PDE4A 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.